144 related articles for article (PubMed ID: 15648294)
1. New strategies in transplantation therapy.
Harousseau JL
Oncology (Williston Park); 2004 Nov; 18(13):1614-5, 1617. PubMed ID: 15648294
[TBL] [Abstract][Full Text] [Related]
2. Stem cell transplant for first relapse from the multiple myeloma research foundation.
Anderson KC; Vesole DH
Oncology (Williston Park); 2006 Dec; 20(14):1818, 1820-1, 1825-6. PubMed ID: 17263130
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.
Anderson KC; Palumbo A;
Oncology (Williston Park); 2005 Apr; 19(4):447-50. PubMed ID: 15934516
[TBL] [Abstract][Full Text] [Related]
4. Myeloma bone disease: pathogenesis and treatment.
Roodman GD;
Oncology (Williston Park); 2005 Jul; 19(8):983-4, 986. PubMed ID: 16131042
[TBL] [Abstract][Full Text] [Related]
5. Prognostic indicators for the diagnosis of multiple myeloma.
Greipp P;
Oncology (Williston Park); 2004 May; 18(5):558-60. PubMed ID: 15209186
[TBL] [Abstract][Full Text] [Related]
6. Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation.
Weber DM
Oncology (Williston Park); 2003 Jun; 17(6):765-7. PubMed ID: 12846120
[TBL] [Abstract][Full Text] [Related]
7. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
8. Amifostine feasibility and efficacy in autologous stem cell transplantation for multiple myeloma.
Stocchi R; Damiani D; Masolini P; Michelutti A; Baccarani M; Tosi P; Fanin R
Haematologica; 2004 Apr; 89(4):ELT02. PubMed ID: 15075115
[No Abstract] [Full Text] [Related]
9. Newly diagnosed multiple myeloma: allograft or autograft?
Gupta D; Kumar L
Natl Med J India; 2007; 20(6):300-1. PubMed ID: 18335797
[No Abstract] [Full Text] [Related]
10. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
Haas PS; Bauchmüller K; Kühnemund A; Finke J; Ihorst G; Engelhardt M
Ann Hematol; 2006 Mar; 85(3):191-3. PubMed ID: 16365747
[No Abstract] [Full Text] [Related]
12. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.
Slovacek L; Slovackova B; Pavlik V; Hrstka Z; Macingova Z; Jebavy L; Horacek JM
Neoplasma; 2008; 55(4):350-5. PubMed ID: 18505348
[TBL] [Abstract][Full Text] [Related]
13. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
[No Abstract] [Full Text] [Related]
14. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases.
Kornacker M; Luft T; Ho AD; Schaefer HJ
Eur J Haematol; 2005 Mar; 74(3):250-3. PubMed ID: 15693795
[TBL] [Abstract][Full Text] [Related]
16. An update: health economics of managing multiple myeloma.
Moeremans K; Annemans L
Eur J Cancer; 2006 Jul; 42(11):1684-91. PubMed ID: 16781867
[TBL] [Abstract][Full Text] [Related]
17. Management of multiple myeloma: the changing landscape.
Reece DE
Blood Rev; 2007 Nov; 21(6):301-14. PubMed ID: 17761373
[TBL] [Abstract][Full Text] [Related]
18. Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity.
Ando T; Yujiri T; Tominaga T; Shinya S; Takahashi T; Nomiyama J; Seguchi M; Matsubara A; Fujii Y; Tanizawa Y
Eur J Haematol; 2005 Feb; 74(2):175-9. PubMed ID: 15654912
[TBL] [Abstract][Full Text] [Related]
19. Role of autologous stem-cell transplantation in multiple myeloma.
Attal M; Harousseau JL
Best Pract Res Clin Haematol; 2007 Dec; 20(4):747-59. PubMed ID: 18070717
[TBL] [Abstract][Full Text] [Related]
20. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
Vela-Ojeda J; García-Ruiz-Esparza MA; Padilla-González Y; Gómez-Almaguer D; Gutiérrez-Aguirre CH; Gómez-Rangel D; Morales-Toquero A; Ruiz-Delgado GJ; Delgado-Lamas JL; Ruiz-Argüelles GJ
Ann Hematol; 2007 Apr; 86(4):277-82. PubMed ID: 17262193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
